Publikationen

Kolbe C, Kauer J, Brinkmann B, Dreger P, Huber W, Muller-Tidow C, . . . Dietrich S, Roider T. Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma. J Immunother Cancer. 2025;13(1).

Roider T, Baertsch MA, Fitzgerald D, Vohringer H, Brinkmann BJ, Czernilofsky F, . . . Dietrich S. Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities. Nat Cell Biol. 2024.

Kobbe G, Bruggemann M, Baermann BN, Wiegand L, Trautmann H, Yousefian S, . . . Dietrich S. Aggressive Lymphoma after CD19 CAR T-Cell Therapy. N Engl J Med. 2024;391(13):1217-26.

Brinkmann BJ, Floerchinger A, Schniederjohann C, Roider T, Coelho M, Mack N, . . . Dietrich S. CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models. Blood. 2024;144(7):784-9.

Rius Rigau A, Liang M, Devakumar V, Neelagar R, Matei AE, Gyorfi AH, . . . Li YN. Imaging mass cytometry-based characterisation of fibroblast subsets and their cellular niches in systemic sclerosis. Ann Rheum Dis. 2024.

Rius Rigau A, Li YN, Matei AE, Gyorfi AH, Bruch PM, Koziel S, . . . Distler JHW, Liang M. Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics. Circ Res. 2024;134(7):875-91.

Jeising S, Nickel AC, Trubel J, Felsberg J, Picard D, Leprivier G, . . . Qin N. A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases. J Neurooncol. 2024.

Liebers N, Bruch PM, Terzer T, Hernandez-Hernandez M, Paramasivam N, Fitzgerald D, . . . Dietrich S. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial. Nat Cancer. 2023;4(12):1648-59.

Herbst SA, Kim V, Roider T, Schitter EC, Bruch PM, Liebers N, . . . Dietrich S. Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies. Blood Adv. 2023;7(19):5925-36.

Qin N, Paisana E, Picard D, Leprivier G, Langini M, Custodia C, . . . Remke M. The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma. J Neurooncol. 2023.

Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, . . . Dietrich S. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood. 2022;140(24):2594-610.

Herbst SA, Vesterlund M, Helmboldt AJ, Jafari R, Siavelis I, Stahl M, . . . Dietrich S. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. Nat Commun. 2022;13(1):6226.

Bruch PM, Giles HA, Kolb C, Herbst SA, Becirovic T, Roider T, . . . Dietrich S. Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL. Mol Syst Biol. 2022;18(8):e10855.

Qin N, Paisana E, Langini M, Picard D, Malzkorn B, Custodia C, . . . Remke M. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis. Neuro Oncol. 2022.

Blumel L, Qin N, Berlandi J, Paisana E, Cascao R, Custodia C, . . . Remke M. Primary cilia contribute to the aggressiveness of atypical teratoid/rhabdoid tumors. Cell Death Dis. 2022;13(9):806.

Roider T, Brinkmann BJ, Kim V, Knoll M, Kolb C, Roessner PM, . . . Dietrich S. An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies. Blood Adv. 2021;5(23):5060-71.

Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, . . . Dietrich S. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021;5(13):2707-16.